Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Stereotaxis, Inc.

STXSAMEX
Healthcare
Medical - Instruments & Supplies
$2.08
$0.01(0.48%)
U.S. Market opens in 13h 37m

Stereotaxis, Inc. Fundamental Analysis

Stereotaxis, Inc. (STXS) shows weak financial fundamentals with a PE ratio of -8.41, profit margin of -78.56%, and ROE of -2.49%. The company generates $0.0B in annual revenue with weak year-over-year growth of 0.55%.

Key Strengths

PEG Ratio-0.08

Areas of Concern

ROE-2.49%
Operating Margin-80.10%
We analyze STXS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -286.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-286.2/100

We analyze STXS's fundamental strength across five key dimensions:

Efficiency Score

Weak

STXS struggles to generate sufficient returns from assets.

ROA > 10%
-51.83%

Valuation Score

Excellent

STXS trades at attractive valuation levels.

PE < 25
-8.41
PEG Ratio < 2
-0.08

Growth Score

Weak

STXS faces weak or negative growth trends.

Revenue Growth > 5%
0.55%
EPS Growth > 10%
-11.11%

Financial Health Score

Excellent

STXS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.48
Current Ratio > 1
1.31

Profitability Score

Weak

STXS struggles to sustain strong margins.

ROE > 15%
-249.40%
Net Margin ≥ 15%
-78.56%
Positive Free Cash Flow
No

Key Financial Metrics

Is STXS Expensive or Cheap?

P/E Ratio

STXS trades at -8.41 times earnings. This suggests potential undervaluation.

-8.41

PEG Ratio

When adjusting for growth, STXS's PEG of -0.08 indicates potential undervaluation.

-0.08

Price to Book

The market values Stereotaxis, Inc. at 17.23 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

17.23

EV/EBITDA

Enterprise value stands at -9.30 times EBITDA. This is generally considered low.

-9.30

How Well Does STXS Make Money?

Net Profit Margin

For every $100 in sales, Stereotaxis, Inc. keeps $-78.56 as profit after all expenses.

-78.56%

Operating Margin

Core operations generate -80.10 in profit for every $100 in revenue, before interest and taxes.

-80.10%

ROE

Management delivers $-2.49 in profit for every $100 of shareholder equity.

-2.49%

ROA

Stereotaxis, Inc. generates $-51.83 in profit for every $100 in assets, demonstrating efficient asset deployment.

-51.83%

Following the Money - Real Cash Generation

Operating Cash Flow

Stereotaxis, Inc. generates limited operating cash flow of $-8.57M, signaling weaker underlying cash strength.

$-8.57M

Free Cash Flow

Stereotaxis, Inc. generates weak or negative free cash flow of $-8.60M, restricting financial flexibility.

$-8.60M

FCF Per Share

Each share generates $-0.09 in free cash annually.

$-0.09

FCF Yield

STXS converts -4.22% of its market value into free cash.

-4.22%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-8.41

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.08

vs 25 benchmark

P/B Ratio

Price to book value ratio

17.23

vs 25 benchmark

P/S Ratio

Price to sales ratio

6.70

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.48

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.31

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-2.49

vs 25 benchmark

ROA

Return on assets percentage

-0.52

vs 25 benchmark

ROCE

Return on capital employed

-0.96

vs 25 benchmark

How STXS Stacks Against Its Sector Peers

MetricSTXS ValueSector AveragePerformance
P/E Ratio-8.4129.28 Better (Cheaper)
ROE-249.40%820.00% Weak
Net Margin-78.56%-19743.00% (disorted) Weak
Debt/Equity0.480.26 Weak (High Leverage)
Current Ratio1.314.69 Neutral
ROA-51.83%-17807.00% (disorted) Weak

STXS outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Stereotaxis, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-31.06%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-287.64%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-36.23%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ